FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044962252> ?p ?o ?g. }

• W2044962252 endingPage "397" @default.
• W2044962252 startingPage "391" @default.
• W2044962252 abstract "Purpose: To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with filgrastim support, in anthracycline- and paclitaxel-pretreated breast cancer (BC) patients. Patients and Methods: Advanced BC patients pretreated with anthracycline- and paclitaxel-based chemotherapy were eligible. DTX (80 mg/m2) and CPT-11 (100 mg/m2) were given biweekly with filgrastim support (300 µg/day on days 4–7). Results: Fifty patients (48 with metastatic and 2 with locally advanced cancer) were enrolled, with a total of 318 cycles being delivered. Thirty-one patients had visceral localizations. All patients had received epirubicin plus paclitaxel, with or without cisplatin, as front-line treatment for advanced disease. Overall, fatigue and diarrhea were the main chemotherapy-related toxicities in this study, being severe in 10 (20%) and 4 (8%) patients. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 18 (36%) and 6 (12%) patients, respectively. Red blood cell transfusions were required in 4 patients. A total of 32 objective responses were registered (overall response rate, ORR = 64%, 95% confidence interval = 49–77%), including 8 complete responses (16%). An additional 8 patients showed stable disease. After a median follow-up of 18 (range 4–29) months, 30 patients were still alive, and 19 were progression free; median progression-free and overall survivals were 10 and 23 months, respectively. Conclusions: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. The very promising ORR and survival outcome observed in this subset of patients with a poor prognosis suggest that this regimen might play a major role in the management of this disease." @default.
• W2044962252 created "2016-06-24" @default.
• W2044962252 creator A5004747884 @default.
• W2044962252 creator A5007515766 @default.
• W2044962252 creator A5015849958 @default.
• W2044962252 creator A5020192377 @default.
• W2044962252 creator A5023150524 @default.
• W2044962252 creator A5036070767 @default.
• W2044962252 creator A5039219972 @default.
• W2044962252 creator A5043699530 @default.
• W2044962252 creator A5054850310 @default.
• W2044962252 creator A5056559714 @default.
• W2044962252 creator A5058301344 @default.
• W2044962252 creator A5061037608 @default.
• W2044962252 creator A5073695437 @default.
• W2044962252 date "2005-01-01" @default.
• W2044962252 modified "2023-09-23" @default.
• W2044962252 title "Biweekly Docetaxel-Irinotecan Treatment with Filgrastim Support Is Highly Active in Antracycline-Paclitaxel-Refractory Breast Cancer Patients" @default.
• W2044962252 cites W1501426350 @default.
• W2044962252 cites W1828283074 @default.
• W2044962252 cites W1841504999 @default.
• W2044962252 cites W1880426265 @default.
• W2044962252 cites W1885306047 @default.
• W2044962252 cites W1970194999 @default.
• W2044962252 cites W1973464765 @default.
• W2044962252 cites W1997638487 @default.
• W2044962252 cites W2038155071 @default.
• W2044962252 cites W2041547498 @default.
• W2044962252 cites W2077492184 @default.
• W2044962252 cites W2114886993 @default.
• W2044962252 cites W2167200229 @default.
• W2044962252 cites W2167805334 @default.
• W2044962252 cites W2183078339 @default.
• W2044962252 cites W2229518396 @default.
• W2044962252 cites W2254197386 @default.
• W2044962252 cites W2268437644 @default.
• W2044962252 cites W2273961595 @default.
• W2044962252 cites W2331708349 @default.
• W2044962252 cites W4293241248 @default.
• W2044962252 doi "https://doi.org/10.1159/000086980" @default.
• W2044962252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16020968" @default.
• W2044962252 hasPublicationYear "2005" @default.
• W2044962252 type Work @default.
• W2044962252 sameAs 2044962252 @default.
• W2044962252 citedByCount "15" @default.
• W2044962252 countsByYear W20449622522013 @default.
• W2044962252 countsByYear W20449622522015 @default.
• W2044962252 crossrefType "journal-article" @default.
• W2044962252 hasAuthorship W2044962252A5004747884 @default.
• W2044962252 hasAuthorship W2044962252A5007515766 @default.
• W2044962252 hasAuthorship W2044962252A5015849958 @default.
• W2044962252 hasAuthorship W2044962252A5020192377 @default.
• W2044962252 hasAuthorship W2044962252A5023150524 @default.
• W2044962252 hasAuthorship W2044962252A5036070767 @default.
• W2044962252 hasAuthorship W2044962252A5039219972 @default.
• W2044962252 hasAuthorship W2044962252A5043699530 @default.
• W2044962252 hasAuthorship W2044962252A5054850310 @default.
• W2044962252 hasAuthorship W2044962252A5056559714 @default.
• W2044962252 hasAuthorship W2044962252A5058301344 @default.
• W2044962252 hasAuthorship W2044962252A5061037608 @default.
• W2044962252 hasAuthorship W2044962252A5073695437 @default.
• W2044962252 hasConcept C121608353 @default.
• W2044962252 hasConcept C126322002 @default.
• W2044962252 hasConcept C141071460 @default.
• W2044962252 hasConcept C143998085 @default.
• W2044962252 hasConcept C2775930923 @default.
• W2044962252 hasConcept C2776694085 @default.
• W2044962252 hasConcept C2776802502 @default.
• W2044962252 hasConcept C2777063308 @default.
• W2044962252 hasConcept C2777292972 @default.
• W2044962252 hasConcept C2778850193 @default.
• W2044962252 hasConcept C2779171977 @default.
• W2044962252 hasConcept C2780259306 @default.
• W2044962252 hasConcept C2780835546 @default.
• W2044962252 hasConcept C2781190966 @default.
• W2044962252 hasConcept C526805850 @default.
• W2044962252 hasConcept C530470458 @default.
• W2044962252 hasConcept C71924100 @default.
• W2044962252 hasConcept C90924648 @default.
• W2044962252 hasConceptScore W2044962252C121608353 @default.
• W2044962252 hasConceptScore W2044962252C126322002 @default.
• W2044962252 hasConceptScore W2044962252C141071460 @default.
• W2044962252 hasConceptScore W2044962252C143998085 @default.
• W2044962252 hasConceptScore W2044962252C2775930923 @default.
• W2044962252 hasConceptScore W2044962252C2776694085 @default.
• W2044962252 hasConceptScore W2044962252C2776802502 @default.
• W2044962252 hasConceptScore W2044962252C2777063308 @default.
• W2044962252 hasConceptScore W2044962252C2777292972 @default.
• W2044962252 hasConceptScore W2044962252C2778850193 @default.
• W2044962252 hasConceptScore W2044962252C2779171977 @default.
• W2044962252 hasConceptScore W2044962252C2780259306 @default.
• W2044962252 hasConceptScore W2044962252C2780835546 @default.
• W2044962252 hasConceptScore W2044962252C2781190966 @default.
• W2044962252 hasConceptScore W2044962252C526805850 @default.
• W2044962252 hasConceptScore W2044962252C530470458 @default.
• W2044962252 hasConceptScore W2044962252C71924100 @default.
• W2044962252 hasConceptScore W2044962252C90924648 @default.
• W2044962252 hasIssue "4-6" @default.

• next